Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
Status:
Completed
Trial end date:
2020-11-20
Target enrollment:
Participant gender:
Summary
New daily persistent headache (NDPH) is a primary headache disorder characterized by the
daily and unremitting headache pain patients experience with a distinct onset. Despite the
known significant impairment associated with NDPH, the process by which some patients with
NDPH recover within months while others do not is unknown.
The investigators propose to refine the clinical definition and suggest a novel mechanism
underlying new daily persistent headache (NDPH) in adolescents. In non-responding patients,
they further aim to investigate low-dose naltrexone for the treatment of new daily persistent
headache.
Adolescents ages 10-17 will be recruited from Boston Children's Hospital Pediatric Headache
Program.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital